Published in Dermatol Surg on December 01, 2010
Global Aesthetics Consensus: Botulinum Toxin Type A-Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications. Plast Reconstr Surg (2016) 0.82
Commentary: Revisiting the data: mild resting glabellar lines improve with onabotulinumtoxinA. Dermatol Surg (2010) 0.75
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache (2010) 4.37
Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol (2005) 2.68
Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol (2012) 2.29
Current status of surgery in dermatology. J Am Acad Dermatol (2013) 1.98
Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. Am J Respir Crit Care Med (2005) 1.58
Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatol Surg (2013) 1.51
A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol (2002) 1.39
Transmission dynamics of tuberculosis in Tarrant county, Texas. Am J Respir Crit Care Med (2002) 1.22
Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol (2007) 1.21
Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord (2010) 1.15
Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg (2003) 1.09
Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg (2005) 1.08
Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg (2005) 1.07
Epsilon-sarcoglycan mutations found in combination with other dystonia gene mutations. Ann Neurol (2002) 1.06
Does directly observed therapy (DOT) reduce drug resistant tuberculosis? BMC Public Health (2011) 1.05
The use of photodynamic therapy in dermatology: results of a consensus conference. J Drugs Dermatol (2006) 1.03
Use of mammographic screening by HIV-infected women in the Women's Interagency HIV Study (WIHS). Prev Med (2002) 1.03
Radiographic and computed tomographic studies of calcium hydroxylapatite for treatment of HIV-associated facial lipoatrophy and correction of nasolabial folds. Dermatol Surg (2008) 1.02
A validated lip fullness grading scale. Dermatol Surg (2008) 1.01
HIV-associated facial lipoatrophy. Dermatol Surg (2002) 1.00
Maternal prenatal exposure to nitrosatable drugs and childhood brain tumours. Int J Epidemiol (2003) 1.00
Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol (2012) 0.99
A validated grading scale for forehead lines. Dermatol Surg (2008) 0.99
Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther (2007) 0.98
Non-animal-based hyaluronic acid fillers: scientific and technical considerations. Plast Reconstr Surg (2007) 0.98
Validated assessment scales for the lower face. Dermatol Surg (2012) 0.97
Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg (2005) 0.96
A review: dietary and endogenously formed N-nitroso compounds and risk of childhood brain tumors. Cancer Causes Control (2005) 0.96
A validated hand grading scale. Dermatol Surg (2008) 0.96
A validated grading scale for marionette lines. Dermatol Surg (2008) 0.95
Validated assessment scales for the upper face. Dermatol Surg (2012) 0.95
Baseline characteristics of participants in the oral health component of the Women's Interagency HIV Study. Community Dent Oral Epidemiol (2004) 0.95
REFINE-1, a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial With ATX-101, an Injectable Drug for Submental Fat Reduction. Dermatol Surg (2016) 0.94
A validated grading scale for crow's feet. Dermatol Surg (2008) 0.94
Efficacy and safety of onabotulinumtoxinA for the treatment of crows feet lines: a multicenter, randomized, controlled trial. Dermatol Surg (2014) 0.93
Single-center, double-blind, randomized study to evaluate the efficacy of 4% lidocaine cream versus vehicle cream during botulinum toxin type A treatments. Dermatol Surg (2005) 0.93
Genetic evidence for an association of the TOR1A locus with segmental/focal dystonia. Mov Disord (2010) 0.93
Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines. J Drugs Dermatol (2011) 0.93
Validated composite assessment scales for the global face. Dermatol Surg (2012) 0.93
A prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatol Surg (2003) 0.92
Facial Soft-Tissue Fillers conference: Assessing the State of the Science. J Am Acad Dermatol (2011) 0.92
Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil (2006) 0.92
Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol (2011) 0.91
Corticospinal excitability accompanying ballistic wrist movements in primary dystonia. Mov Disord (2004) 0.91
Patient-reported outcomes with botulinum neurotoxin type A. J Cosmet Laser Ther (2007) 0.91
Prevalence of anal intraepithelial neoplasia defined by anal cytology screening and high-resolution anoscopy in a primary care population of HIV-infected men and women. Dis Colon Rectum (2011) 0.90
Estimation of radiographic doses in a case-control study of acute myelogenous leukemia. Health Phys (2003) 0.90
An international case-control study of adult diet and brain tumor risk: a histology-specific analysis by food group. Ann Epidemiol (2009) 0.89
Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter? Dermatol Surg (2007) 0.89
Management of injected hyaluronic acid induced Tyndall effects. Lasers Surg Med (2006) 0.89
Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatol Surg (2015) 0.89
Phenotypic spectrum and sex effects in eleven myoclonus-dystonia families with epsilon-sarcoglycan mutations. Mov Disord (2008) 0.89
Development of onabotulinumtoxinA for chronic migraine. Ann N Y Acad Sci (2014) 0.88
The natural history of polymethylmethacrylate microspheres granulomas. Dermatol Surg (2007) 0.87
Eyebrow height after botulinum toxin type A to the glabella. Dermatol Surg (2007) 0.87
Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol (2009) 0.87
Botulinum toxin type A (BOTOX) for treatment of migraine. Dis Mon (2002) 0.87
Heterogeneity of crow's feet line patterns in clinical trial subjects. Dermatol Surg (2015) 0.87
Cerebrospinal fluid sodium rhythms. Cerebrospinal Fluid Res (2010) 0.86
Innovative technology for the assisted delivery of intensive voice treatment (LSVT®LOUD) for Parkinson disease. Am J Speech Lang Pathol (2012) 0.86
Patient-reported outcomes of bimatoprost for eyelash growth: results from a randomized, double-masked, vehicle-controlled, parallel-group study. Aesthet Surg J (2013) 0.86
Residential magnetic field exposure and breast cancer risk: a nested case-control study from a multiethnic cohort in Los Angeles County, California. Am J Epidemiol (2003) 0.85
A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. J Am Acad Dermatol (2009) 0.85
Cerebrospinal fluid sodium increases in migraine. Headache (2006) 0.85
Dose response with onabotulinumtoxinA for post-stroke spasticity: a pooled data analysis. Mov Disord (2010) 0.85
A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia. Neurogenetics (2003) 0.84
Botulinum toxin A: its expanding role in dermatology and esthetics. Am J Clin Dermatol (2003) 0.84
A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. J Drugs Dermatol (2009) 0.84
A validated facial grading scale: the future of facial ageing measurement tools? J Cosmet Laser Ther (2010) 0.84
Executive function changes before memory in preclinical Alzheimer's pathology: a prospective, cross-sectional, case control study. PLoS One (2013) 0.84
OnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar lines. Dermatol Surg (2012) 0.83
Evaluation of injectable calcium hydroxylapatite for the treatment of facial lipoatrophy associated with human immunodeficiency virus. Dermatol Surg (2008) 0.83
A validated brow positioning grading scale. Dermatol Surg (2008) 0.83
Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. BMC Neurol (2014) 0.82
Surgical pearl: the use of the Ultra-Fine II short needle 0.3-cc insulin syringe for botulinum toxin injections. J Am Acad Dermatol (2002) 0.82
Surgical management of airway dysfunction in Parkinson's disease compared with Parkinson-plus syndromes. Ann Otol Rhinol Laryngol (2013) 0.81
Combination therapy with BOTOX and fillers: the new rejuvnation paradigm. Dermatol Ther (2006) 0.81
Monopolar radiofrequency treatment of human eyelids: a prospective, multicenter, efficacy trial. Lasers Surg Med (2006) 0.80
Patient satisfaction and safety with aesthetic onabotulinumtoxinA after at least 5 years: a retrospective cross-sectional analysis of 4,402 glabellar treatments. Dermatol Surg (2015) 0.80
Consensus statement regarding storage and reuse of previously reconstituted neuromodulators. Dermatol Surg (2015) 0.80
Treatment of high-grade anal intraepithelial neoplasia with infrared coagulation in a primary care population of HIV-infected men and women. Dis Colon Rectum (2012) 0.80
Fusion of Golgi-derived vesicles mediated by SNAP-25 is essential for sympathetic neuron outgrowth but relatively insensitive to botulinum neurotoxins in vitro. FEBS J (2014) 0.78
Clinical Experience With 11,460 mL of a 20-mg/mL, Smooth, Highly Cohesive, Viscous Hyaluronic Acid Filler. Dermatol Surg (2015) 0.78
Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section. Ann Otol Rhinol Laryngol (2003) 0.78
Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatol Surg (2010) 0.78
Upper Face: Clinical Anatomy and Regional Approaches with Injectable Fillers. Plast Reconstr Surg (2015) 0.78
Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol (2014) 0.78
ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: Rationale and Design. Cell Transplant (2016) 0.77
Efficacy and Safety of OnabotulinumtoxinA Treatment of Forehead Lines: A Multicenter, Randomized, Dose-Ranging Controlled Trial. Dermatol Surg (2016) 0.77
Botulinum treatment of forehead wrinkles. Plast Reconstr Surg (2006) 0.77
Effects of OnabotulinumtoxinA treatment for crow's feet lines on patient-reported outcomes. Dermatol Surg (2015) 0.77
Botulinum toxin type A for the treatment of glabellar rhytides. Dermatol Clin (2004) 0.77
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines. Dermatol Surg (2015) 0.77